Log In
Print
BCIQ
Print
Print this Print this
 

AP26113

  Manage Alerts
Collapse Summary General Information
Company Ariad Pharmaceuticals Inc.
DescriptionDual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR)
Molecular Target Anaplastic lymphoma kinase (ALK) ; Epidermal growth factor receptor (EGFR)
Mechanism of ActionAnaplastic lymphoma kinase (Ki-1) (ALK) inhibitor
Latest Stage of DevelopmentPhase I/II
IndicationNon-small cell lung cancer (NSCLC)
Partner

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today